Yuandong Biological (688513.SH): Injection YLSH003 initiates Phase I/II clinical trials and completes the first subject's enrollment.

Zhongtong Finance APP News, Yuandong Biotech (688513.SH) announced that its wholly-owned subsidiary, Ullo Biotech (Shanghai) Co., Ltd. ("Shanghai Ullo"), independently developed a class 1 biopharmaceutical injection YLSH003 is currently undergoing Phase I/II clinical trials for advanced solid tumors. The first subject has successfully entered the dosing group recently.